RemeGen Reports Strong H1 2024 Growth and Clinical Advances

RemeGen Co. Ltd. Class H (HK:9995) has released an update.

RemeGen Co., Ltd. has reported a 76.5% revenue increase in the first half of 2024 compared to the previous year, driven by strong sales of its autoimmune and tumor treatments, telitacicept and disitamab vedotin. The company has achieved significant milestones, including FDA fast track designation for telitacicept, completion of patient enrollment in Phase III trials, and publication of positive clinical study results. Additionally, disitamab vedotin has shown promising results in various phases of clinical trials for different cancers, with one study achieving its primary endpoint and receiving breakthrough therapy designation.

For further insights into HK:9995 stock, check out TipRanks’ Stock Analysis page.